McNeel Douglas G, Malkovsky Miroslav
Department of Medicine, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792, USA.
Immunol Lett. 2005 Jan 15;96(1):3-9. doi: 10.1016/j.imlet.2004.06.009.
Prostate cancer is a leading cause of cancer morbidity and mortality in the United States. Animal and clinical studies performed four decades ago suggested that immunological approaches might be useful for the treatment of prostate cancer. The wealth of information that has been learned over the last two decades has suggested many new directions to the immune-based therapy of prostate cancer, including passive and active immunotherapy approaches. The findings from current trials, and the likely combination of current immunotherapy approaches with conventional therapies, portends a hopeful future for the treatment of prostate cancer.
前列腺癌是美国癌症发病和死亡的主要原因。四十年前进行的动物和临床研究表明,免疫疗法可能对前列腺癌的治疗有用。过去二十年中积累的大量信息为前列腺癌的免疫治疗提出了许多新方向,包括被动和主动免疫治疗方法。当前试验的结果,以及当前免疫治疗方法与传统疗法的可能结合,预示着前列腺癌治疗的前景充满希望。